King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Thera...(y few studies have examined the extent o...),Health

Date:6/25/2009

y few studies have examined the extent of the pharmacokinetic (PK) and pharmacodynamic (PD) interaction between them, particularly when taken at therapeutic doses. A literature review was conducted to gather published data on the safety risks associated with alcohol-opioid interactions, alcohol-induced dose-dumping, and the methodology used to characterize such interactions. The review found that the combination of EtOH and select opioids at the studied doses does not appear to produce additive pharmacodynamic effects, while the pharmacokinetic profiles may be affected for certain other opioids when combined with EtOH. Additional studies would be required to further assess and verify these findings

About ACUROX(R) Tablets

ACUROX(R) is an investigational patented, orally administered, immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient with a proposed indication for the relief of moderate- to-severe pain. ACUROX(R) utilizes Acura's proprietary Aversion(R) Technology. Aversion(R) Technology is a patented triple-action composition of niacin and inactive ingredients. These ingredients can generate a temporary, unpleasant effect if orally over-consumed, turn dissolved tablets into a thick gelatinous mixture making it difficult to draw into a syringe, or produce a mild burning sensation in the nostrils when crushed and snorted. There is no evidence that ACUROX(R)'s triple-action combination of niacin and inactive ingredients reduces its abuse liability.

About EMBEDA(TM)

EMBEDA(TM) is an investigational long-acting opioid analgesic that contains extended-release morphine pellets, each with a sequestered core of naltrexone, an opioid antagonist. The formulation is designed to work such that if taken as directed, the morphine would relieve pain while the sequestered naltrexone would pass through the body with no intended clinical effect. If EMBEDA(TM) is crushed
'/>"/>

SOURCE King Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate